Warfarin label to include genetic test suggestion

Call it the FDA's official ushering-in of the gene-tailored drug era. The agency is suggesting that doctors examine their patients' genetic profiles before prescribing the anticoagulant warfarin, which can cause bleeding complications in some people. Warfarin is prescribed to some 2 million annually, and results in about 30,000 E.R. visits each year.

The FDA isn't ordering doctors to do so, but the suggested testing is incorporated in the drug's label. It's the first time the agency has included language about genetic profiling in such a widely used drug. People with unusual variations in two key genes - one that regulates metabolism and one that determines sensitivity to warfarin's blood-thinning mechanism - should be started at lower doses, experts say.

- here's the article from The Washington Post
- see the FierceBiotech report

Related Articles:
Diagnostics tied to new drugs. Report
Personalized medicine advances with new genetic test. Report
The brave new world of personalized medicine. Report
Genetic testing advances as insurers balk. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.